Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.